TrialClinical drug investigation2024

Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.

Wenwang Lang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.